Cell Therapeutics, Inc. Announces Filing of Form 10-K

SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the filing of its annual report on Form 10-K for the year ended December 31, 2007 has now been timely completed. This filing is available for review on CTI's Web site at http://www.celltherapeutics.com/ or on the Securities and Exchange Commission's Web site at
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also announced that its independent auditor's report included in the annual report on Form 10-K contains a "going concern" qualification.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.comhttp://www.celltherapeutics.com/media.htm

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.comhttp://www.celltherapeutics.com/investors.htm

First Call Analyst:
FCMN Contact:

Source: Cell Therapeutics, Inc.

CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
media@ctiseattle.com, or investors, Leah Grant, +1-206-282-7100, fax,
+1-206-272-4434, invest@ctiseattle.com, both of Cell Therapeutics, Inc.

Web site: http://www.celltherapeutics.com/

2008-03-28 20:31:58 0322540 PRNEWSWIRE